Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0CWADI
ADC Name	AZD-9592
Synonyms	AZD9592; AZD 9592 Click to Show/Hide
Organization	AstraZeneca PLC
Drug Status	Phase 1
Indication	In total 3 Indication(s) Head and neck cancer [ICD11:2B60-2B6E] Phase 1 Non-small cell lung cancer [ICD11:2C25] Phase 1 Solid tumors [ICD11:2A00-2A0Z\|2B50-2F9Z] Phase 1
Drug-to-Antibody Ratio	6
Structure
	3D MOL	2D MOL
Antibody Name	Undisclosed
Antigen Name	Epidermal growth factor receptor (EGFR); Hepatocyte growth factor receptor (MET)		Antigen Info
Payload Name	Undisclosed
Linker Name	Undisclosed

General Information of The Activity Data Related to This ADC

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	NCT Number	Clinical Status	Clinical Trial Description
Undisclosed	NCT05647122	Phase 1	A phase 1, multicenter, open-label, first-in-human, dose escalation and expansion study of AZD9592 as monotherapy and in combination with anti-cancer agents in patients with advanced solid tumors.

Full List of Activity Data of This Antibody-drug Conjugate

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Patients Enrolled	Patients with metastatic non-small cell lung cancer (mNSCLC) with EGFRm (sensitizing L858R mutation or exon 19 deletions) or EGFR wild-type, or recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Administration Dosage	.
*Related Clinical Trial*
NCT Number	NCT05647122	Clinical Status	Phase 1
Clinical Description	A phase 1, multicenter, open-label, first-in-human, dose escalation and expansion study of AZD9592 as monotherapy and in combination with anti-cancer agents in patients with advanced solid tumors.

References

Ref 1	A first-in-human study of the novel antibody-drug conjugate (ADC) AZD9592 as monotherapy or combined with other anticancer agents in patients (pts) with advanced solid tumors. J Clin Oncol. 2023 41:16_suppl, TPS3156-TPS3156.